Repotrectinib Shows Promising Interim Results in ROS1 and ...

Repotrectinib Shows Promising Interim Results in ROS1+ and ...

Objective response rates for repotrectinib in patients with ROS1-positive non–small cell lung cancer and NTRK fusion-positive advanced solid ...

Repotrectinib Garners Positive CHMP Opinion for ROS1+ NSCLC ...

Repotrectinib shows promising efficacy in ROS1-positive NSCLC and NTRK-positive solid tumors, with high overall response rates in clinical ...

Repotrectinib Shows Promising Activity in ROS1+ NSCLC - OncLive

Repotrectinib (TPX-0005) demonstrates a clinically meaningful and durable benefit across multiple doses in patients with ROS1 ...

Repotrectinib Shows Promising Activity in ROS1+ NSCLC

“Repotrectinib (TPX-0005) demonstrated a clinically meaningful and durable benefit across multiple doses in patients with ROS1 fusion–positive ...

Repotrectinib Shows Frontline Responses in ROS1+ Advanced ...

These results showed proof for the use of repotrectinib in the first-line setting for patients with ROS1-positive NSCLC after chemotherapy or ...

Repotrectinib Shows Encouraging Safety, Efficacy for Patients With ...

Early results from the first-in-human phase I/II clinical trial of the tyrosine kinase inhibitor (TKI) repotrectinib, presented May 31 ...

Repotrectinib exhibits potent anti-tumor activity in treatment-naive ...

Results: Repotrectinib potently inhibited in vitro and in vivo tumor growth and ROS1-downstream signal in treatment-naïve YU1078 compared with clinically ...

Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for ...

“The TRIDENT-1 study showed that treatment with repotrectinib results in high response rates with promising durability in patients with ROS1 ...

MA11.07 Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients ...

In the Phase 1 portion of TRIDENT-1 study, repotrectinib demonstrated encouraging overall clinical activity in patients (pts) with ROS1 fusion+ NSCLC and TRK ...

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK ...

As shown in the preliminary clinical data presented in this report, repotrectinib has demonstrated proof-of-concept CNS activity against untreated brain ...

Repotrectinib Shrinks ROS1-Positive NSCLC Tumors - NCI

... shrank tumors in a substantial number of people with advanced NSCLC with ROS1 fusions, results of the TRIDENT-1 trial show.

FDA Approves New Drug for Non-Small Cell Lung Cancer With ...

Learn more about the new FDA-approved drug repotrectinib (AugtyroTM), which targets ROS1 fusions in lung cancer and other cancer types.

Repotrectinib Yields Enduring Responses in ROS1+ NSCLC

Treatment with repotrectinib in patients with ROS1 fusion–positive non–small cell lung cancer results in mostly low-grade adverse effects in ...

FDA Approves Repotrectinib for NTRK-Positive Locally Advanced ...

Repotrectinib has also shown significant efficacy in ROS1 fusion-positive non¬–small cell lung cancer (NSCLC), which was also studied in the ...

Repotrectinib, an Investigational TKI, Induces Response in ROS1 ...

Chicago, IL—Expanded data from an early phase 1/2 clinical trial showed ... The preliminary efficacy analysis was conducted in 33 patients with ROS1-positive ...

Safety and preliminary clinical activity of repotrectinib in patients with ...

Background: Repotrectinib is a next-generation ROS1/TRK/ALK TKI inhibiting ROS1 with > 90-fold greater potency than crizotinib. Preclinical studies showed ...

Repotrectinib Receives Priority Review From FDA for NTRK+ Solid ...

Repotrectinib was previously approved by the FDA in November 2023, for the treatment of adult patients with locally advanced or metastatic ROS1- ...

Safety and preliminary clinical activity of repotrectinib in patients with ...

Repotrectinib was well tolerated and demonstrated encouraging overall clinical activity in pts with ROS1 fusion-positive NSCLC and TRK fusion-positive solid ...

OA09 Preliminary Clinical Activity of Repotrectinib (TPX-0005) in ...

However, acquired resistance inevitably develops, resulting in disease relapse. Repotrectinib is a potent next-generation ROS1/TRK/ALK TKI, which inhibits ROS1 ...

Advances and future directions in ROS1 fusion-positive lung cancer

Based on TRIDENT-1, the FDA approved repotrectinib in 2023 for line-agnostic treatment for locally advanced or metastatic ROS1+ NSCLC.43 ...